Melanoma Treatments: Advances and Mechanisms.

Abstract

Advances in the understanding of the molecular pathogenesis of melanoma and in cancer immunology have led to the rational design and recent clinical implementation of a variety of novel therapies for metastatic melanoma. BRAF and MEK inhibitors that target the MAPK pathway have high rates of clinical response in BRAF-mutant melanoma. Therapies that modulate the immune response to melanoma, including monoclonal antibodies that interfere with pathways that inhibit T-cell function, have been shown to be effective in melanoma. Lessons learned from these encouraging results are driving the development of new treatments for melanoma and other cancers. This review will focus on the science and clinical findings related to targeted therapies that inhibit BRAF or MEK as well as the immunotherapies that block the CTLA-4 or PD-1 pathways. Other experimental and combinatorial therapeutic approaches will also be discussed.

• Authors: Alexander Marzuka, Laura Huang, Nicholas Theodosakis, Marcus Bosenberg
• Journal: Journal of cellular physiology (J Cell Physiol) Vol. 230 Issue 11 Pg. 2626-33 (Nov 2015) ISSN: 1097-4652 [Electronic] United States
• PMID: 25899612 (Publication Type: Journal Article, Review)
• Copyright: © 2015 Wiley Periodicals, Inc.

Chemical References

• Antibodies, Monoclonal
• CTLA-4 Antigen
• PDCD1 protein, human
• Programmed Cell Death 1 Receptor
• Protein Kinase Inhibitors
• BRAF protein, human
• Proto-Oncogene Proteins B-raf
• MAP Kinase Kinase Kinases

Topics

• Antibodies, Monoclonal (therapeutic use)
• CTLA-4 Antigen (genetics, metabolism)
• Humans
• MAP Kinase Kinase Kinases (antagonists & inhibitors, genetics)
• Melanoma (drug therapy, genetics, pathology)
• Mutation
• Programmed Cell Death 1 Receptor (genetics, metabolism)
• Protein Kinase Inhibitors (adverse effects, therapeutic use)
• Proto-Oncogene Proteins B-raf (antagonists & inhibitors, genetics)
• Signal Transduction
• Skin Neoplasms (drug therapy, genetics, pathology)